800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

view all Clinical Trials

Overview

This is a Phase III randomized, double-blind, parallel group, multi-center event-driven study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants with COPD who are at risk of a cardiopulmonary event.

Clinical Trial Information

Protocol

TIRB#: 31693

Phase

3

Condition(s)

Chronic Obstructive Pulmonary Disease (COPD)

Investigator

Gerard Criner, MD

Coordinator

Helga Criner

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)